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Introduction: The selective neurokinin-1 receptor antagonist aprepitant is effective in the 
treatment of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated 
with both moderately and highly emetogenic chemotherapy. Fosaprepitant has been developed 
as an intravenous prodrug of aprepitant.
Aims: To update the evidence underlying the use of fosaprepitant to prevent CINV .
Evidence review: Aprepitant in combination with a serotonin antagonist and a corticosteroid con-
trols acute and delayed symptoms of CINV in patients receiving moderately to highly emetogenic 
chemotherapy. Bioequivalence of fosaprepitant with aprepitant has recently been demonstrated, 
which has led to its inclusion in clinical guidelines for treatment of acute CINV with highly, and 
some regimens of moderately, emetogenic chemotherapy. Early studies of the clinical efficacy 
of fosaprepitant have shown improvement over treatment with ondansetron. Both aprepitant and 
fosaprepitant are well tolerated with most adverse events observed of mild or moderate intensity. 
Conflicting economic evidence has shown that whilst aprepitant provides an increased quality 
of life in patients treated for CINV , there are differing views over its absolute cost in relation 
to standard therapy. The incremental cost-effectiveness ratio of aprepitant, however, appears to 
lie within acceptable bounds.
Place in therapy: Fosaprepitant and aprepitant are recommended in guidelines for preventing 
CINV due to moderately and highly emetogenic chemotherapy. Fosaprepitant is bioequivalent 
to aprepitant, and could offer potential benefits for patients who may be unable to tolerate oral 
administration of antiemetics during an episode of nausea or vomiting.
Keywords: fosaprepitant, aprepitant, chemotherapy, nausea, vomiting
Core evidence place in therapy summary for fosaprepitant in the prevention of 
chemotherapy-induced nausea and vomiting
Outcome measure Evidence Implications
Pharmacologic evidence
Bioequivalence of 
fosaprepitanta with aprepitant
Clear Fosaprepitant 115 mg is bioequivalent to aprepitant 
125 mg and may be used interchangeably
Patient-oriented evidence
Control of acute and delayed 
emesis
Clear Adding aprepitant to standard antiemetic therapy 
with dexamethasone plus a serotonin antagonist 
improves control of emesis and reduces need for 
rescue medication in patients receiving moderately 
or highly emetogenic chemotherapy
Control of nausea Clear Adding aprepitant to standard antiemetic therapy 
with dexamethasone plus a serotonin antagonist 
reduces symptoms of nausea in patients receiving 
moderately or highly emetogenic chemotherapy
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Scope, aims, and objectives
Fosaprepitant (Ivemend®, Merck) is a new intravenous 
prodrug formulation of the oral neurokinin-1 (NK1) receptor 
antagonist aprepitant (Emend®, Merck). Aprepitant blocks 
the activity of substance P at NK1 receptors in the brain and 
has been approved by the US Food and Drug Administration 
(FDA) for prevention of nausea and vomiting in combina-
tion with other antiemetics following moderately or highly 
emetogenic chemotherapy in patients with cancer.
Fosaprepitant received FDA and European Medicines 
Agency (EMEA) approval in January 2008 for prevention 
of acute and delayed nausea and vomiting associated with 
initial and repeated courses of highly and moderately emeto-
genic cancer chemotherapy, including high-dose cisplatin, 
in combination with other antiemetic agents.
The use of an intravenous formulation offers potential 
benefits for patients who may be unable to tolerate oral 
administration of antiemetics during an episode of nausea 
or vomiting. This review assesses the evidence for the use 
of fosaprepitant and updates the evidence for aprepitant in 
prophylaxis of acute and delayed chemotherapy-induced 
nausea and vomiting (CINV).
Methods
A previous review has conducted a thorough investigation of 
the use of aprepitant in preventing CINV in the clinical setting 
up to 2006.1 The methodology employed here provides an 
update to this analysis and also investigates the recent intro-
duction of fosaprepitant as an alternative to aprepitant in the 
management of CINV .
An English language literature search was conducted on 
August 8, 2008 in the PubMed database (http://www.ncbi.
nlm.nih.gov/entrez) using the search term “fosaprepitant” 
and limits “Publication Date from July 1, 2006 to July 31, 
2008, English.”
A total of 80 papers were initially identified. Hand 
searching to remove articles unrelated to CINV (for example 
postoperative nausea and vomiting), general overviews 
of the therapy area, clinical studies where aprepitant or 
fosaprepitant were not primary investigational drugs, and 
pharmacokinetic analyses, yielded a total of eight full 
papers for evaluation (Table 1). Two additional studies were 
identitfied.
Disease overview
Nausea and vomiting are a common side effect of chemo-
therapy, with some drugs such as cisplatin, especially at 
higher does, causing emesis in most patients.2 Avoidance 
of these symptoms is desirable due to the considerable 
negative impact of an episode of CINV such as dehydration, 
impairment of activity and quality of life, and electrolyte 
imbalance.3 More serious consequences of prolonged CINV 
include organ damage, esophageal tearing, and pneumonia 
from aspired vomit.3 As well as a being a further burden to 
patients’ health and quality of life, CINV can also disrupt 
(Continued)
Outcome measure Evidence Implications
– –
Patient satisfaction Clear Patients more satisfied with their antiemetic 
therapy when aprepitant added; less impact of 
symptoms on daily activities
Economic evidence
Cost effectiveness  Limited  Acquisition costs of fosaprepitant may be partially 
offset by savings in overall direct costs
aFosaprepitant is the intravenous formulation of aprepitant.
Table 1 Evidence base include in the review
Category Number of records
  Full papers Abstracts
initial search 80 0
  records excluded 72 0
  records included 8 0
Additional studies identified 2 0
Total records included 10 0
Level 1 clinical evidence (systematic 
review, meta analysis)
1 0
Level 2 clinical evidence (rCT) 4 0
Level 3 clinical evidence
  Trials other than rCT 0 0
  Case reports 2 0
Economic evidence 3 0
Notes: For definitions of levels of evidence, see Core Evidence website (http://www.
dovepress.com/core-evidence-journal).
Abbreviation: rCT, randomized controlled trial.Core Evidence 2010:5 79
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and delay chemotherapy schedules. Prevention or alleviation 
of symptoms can help to minimize these delays allowing 
patients to continue with their cancer treatment.
CINV is more likely to occur in young, female patients 
and less likely following alcohol abuse.4 The choice of drug 
is also a major determinant of the severity of CINV with 
emetogenicity varying widely across available chemothera-
peutic agents.5
CINV may occur at any of three time points surrounding 
chemotherapy. Acute CINV is observed within 24 hours 
of commencing chemotherapy and may last for several 
hours. It usually presents within 1–2 hours, although with 
agents such as carboplatin effects may not be seen for up to 
10 hours.4 A second type, delayed CINV , occurs more than 
24 hours after chemotherapy has ended and may continue 
for a number of days. This can often be worse than an acute 
episode as the duration may be longer and it is more likely 
to occur in a patient’s home, away from immediate medical 
assistance.2,4 The third and final type is anticipatory CINV , 
which, as the name suggests, is based on prior negative expe-
riences and occurs before chemotherapy has begun.
Acute and delayed CINV arise through the effect of 
chemotherapeutic agents acting as noxious stimuli within the 
body, in turn activating the vomiting center located within 
the medullary region of the brain and leading to nausea and 
emesis. It is currently thought that acute CINV is related to 
activity in peripheral serotoninergic pathways, whereas the 
action of substance P at NK1 receptors is responsible for 
delayed symptoms2,6 (Figure 1). Prior experience of CINV 
can lead to a causal association in some patients between 
chemotherapy and resultant nausea and emesis, leading to 
an anticipatory psychologic response prior to subsequent 
chemotherapy sessions that can be difficult to manage.
Current therapy options
Treatments used in the prophylaxis and control of CINV 
involve a variety of antiemetic drugs including serotonin 
receptor antagonists (eg, ondansetron, palonosetron), corti-
costeroids (eg, dexamethasone), and dopamine antagonists 
(eg, metoclopramide). The orally administered NK1 receptor 
antagonist aprepitant is a relatively new addition to the current 
range of therapy options and has recently been reformulated 
as the intravenous preparation, fosaprepitant.
Drug treatments are focused primarily on the prevention 
of acute CINV as this also has the effect of reducing delayed 
and anticipatory symptoms.4,7 A number of clinical, evidence-
based guidelines have been produced for the management 
of CINV (Table 2).
Corticosteroids and serotonin antagonists have been the 
mainstay of CINV treatment due to highly and moderately 
emetogenic chemotherapy. Used together these drugs have an 
efficacy of 60%–70% in patients experiencing acute CINV8 
and both classes of drug are well tolerated.2,4,8 Augmenting 
this combination with aprepitant has been proven to be 
effective in 80%–90% of acute cases of CINV in highly9,10 
or moderately11 emetogenic chemotherapy. Guidelines now 
approve aprepitant alongside a serotonin antagonist and a 
corticosteroid for acute and delayed CINV with all forms of 
highly emetogenic chemotherapy, and the use of these three 
drugs in combination has a safety profile similar to that of a 
serotonin antagonist and a corticosteroid.9,10
Guidelines do not yet recommend aprepitant therapy 
for all moderately emetogenic chemotherapeutic regimens. 
However, for treatment of CINV following an anthracycline 
plus cyclophosphamide, aprepitant is now suggested in all 
four major treatment guidelines (Table 2).
For low to moderately emetogenic chemotherapy, 
corticosteroids alone are effective in up to 90% of patients.4 
National Comprehensive Cancer Network (NCCN) 
guidelines also recommend prochlorperazine or the dopamine 
antagonist metoclopramide as alternatives to a corticoste-
roid for the treatment of acute or delayed CINV in chemo-
therapy with low emetogenic potential. Diphenhydramine 
can also be coadministered with a dopamine antagonist 
to counteract the potential for extrapyramidal adverse 
effects,8 however, the use of dopamine antagonists is now 
recommended only as salvage for patients unresponsive to 
serotonin antagonists.4
Unmet needs
The introduction of aprepitant into the therapeutic 
regimen for CINV has led to considerable improvement in 
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Figure 1 Proposed mechanism and time course of chemotherapy-induced nausea and 
vomiting with cisplatin.  Copyright © 2005, Future Drugs Ltd.   Adapted with permission 
from Aguilar EA, Figueiras MC, Cortes-Funes H, et al. Clinical practice guidelines on 
antiemetics in oncology. Expert Rev Anticancer Ther. 2005;5(6):963–972.Core Evidence 2010:5 80
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Table 2 Evidence-based clinical practice guidelines for the prevention of acute and delayed chemotherapy-induced nausea and vomiting
Guideline Emetogenic potential Acute CINV Delayed CINV
ASCO15 High Serotonin antagonist + dexamethasone  
+aprepitant before chemotherapy
Dexamethasone + aprepitant
Moderate: patients receiving 
anthracycline + cyclophosphamide
Aprepitant + serotonin antagonist  
+ dexamethasone before chemotherapy
Aprepitant
Moderate Serotonin antagonist + dexamethasone Serotonin antagonist or 
dexamethasone
Low Dexamethasone No routine antiemetic
Minimal No routine antiemetic No routine antiemetic
ESMO16 High Serotonin antagonist + corticosteroid 
+ aprepitant
Corticosteroid + aprepitant
Moderate: patients receiving 
anthracycline + cyclophosphamide
Serotonin antagonist + dexamethasone 
+ aprepitant
Dexamethasone or aprepitant
Moderate Serotonin antagonist + corticosteroid Serotonin antagonist or 
corticosteroid
Low Single agent, eg, corticosteroid No routine antiemetic
Minimal No routine antiemetic No routine antiemetic
MASCC17 High Serotonin antagonist + dexamethasone 
+ aprepitant or fosaprepitant before 
chemotherapy
Dexamethasone + aprepitant
Moderate: patients receiving 
anthracycline + cyclophosphamide
Serotonin antagonist + dexamethasone 
+ aprepitant or fosaprepitant before 
chemotherapy (women specifically)
Dexamethasone or aprepitant
Moderate Serotonin antagonist + dexamethasone in 
first course
Dexamethasone or serotonin 
antagonist
Low Single agent, eg, corticosteroid None stated
Minimal No routine antiemetic None stated
NCCN18 High Aprepitant or fosaprepitant + serotonin 
antagonist + dexamethasone ± lorazepama 
before chemotherapy
Aprepitant + dexamethasone ± 
lorazepama before chemotherapy
Moderate: select patients 
receiving cisplatin, carboplatin, 
doxorubicin, epirubicin, ifosfamide, 
irinotecan, methotrexate
Aprepitant or fosaprepitant + serotonin 
antagonist + dexamethasonea before 
chemotherapy
Aprepitant ± dexamethasone ± 
lorazepama
Moderate Serotonin antagonist + dexamethasone ± 
lorazepama
Dexamethasone or serotonin 
antagonist ± lorazepama
Low Dexamethasone or prochlorperazine or 
metoclopramide ± lorazepama before 
chemotherapy
Dexamethasone or 
prochlorperazine or 
metoclopramide ± lorazepama 
before chemotherapy
  Minimal No routine antiemetic No routine antiemetic
Note: a± H2 blocker or proton pump inhibitor.
Abbreviations: ASCO, American Society of Clincal Oncology; CiNv, chemotherapy-induced nausea and vomiting; ESMO, European Society for Medical Oncology; MASCC, 
Multinational  Association of Supportive Care in Cancer; NCCN, National Comprehensive Cancer Network.
treatment outcomes for both the acute and delayed phases 
of CINV. The combination of corticosteroid, serotonin 
antagonist, and aprepitant has been shown to have up to 
90% efficacy in the prevention of both acute and delayed 
CINV .9–11 However, the current formulation of aprepitant for 
oral delivery, though highly effective, may not be optimal 
for all clinical situations.
Oral administration may not always be feasible, such 
as in patients who are not fully conscious or those who 
cannot tolerate oral drugs during an episode of nausea 
and vomiting. In fact, administration of a drug via the oral 
route may even cause or exacerbate symptoms and emesis 
shortly after receiving oral aprepitant could result in the 
loss of some or the whole of the dose. For patients on Core Evidence 2010:5 81
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chemotherapy at high risk of oral mucositis, such as those 
with head and neck cancer, oral formulations may also be 
unsuitable. An alternative method of administration would 
help to alleviate these issues.
rationale for fosaprepitant
Fosaprepitant received approval from both the FDA and 
EMEA in January 2008 for the prevention of CINV associ-
ated with highly and moderately emetogenic chemotherapy. 
It is an intravenous prodrug of the orally administered anti-
emetic aprepitant, the first clinically available NK1 receptor 
antagonist to be indicated for CINV. The mechanism of 
action of aprepitant in blocking substance P activity at NK1 
receptors in the brain2,6 provides a new means of preventing 
CINV and offers synergistic improvement in the manage-
ment of symptoms when used alongside corticosteroids 
and serotonin antagonists. Patients can now be assured of 
considerably improved outcomes in the prevention of CINV 
using these drugs.
As a reformulated prodrug, fosaprepitant avoids the prob-
lems associated with oral administration, and when infused 
intravenously is rapidly converted to active aprepitant by 
phosphatase enzymes.12,13 An investigation by Lasseter and 
colleagues14 demonstrated bioequivalence of fosaprepitant 
to aprepitant, and consequently the pharmacologic effects 
of fosaprepitant are the same as, and directly attributable to, 
aprepitant. Recent revisions to the Multinational Association 
of Supportive Care in Cancer (MASCC) and NCCN clinical 
guidelines also support this bioequivalence in advising that 
the two drugs may be used interchangeably on the first day 
of intervention for acute CINV associated with highly or 
moderately emetogenic chemotherapy (Table 2).
Clinical evidence with fosaprepitant
In reviewing clinical evidence for the use of fosaprepitant in 
treatment of CINV , it must be remembered that its pharma-
cologic activity is entirely dependent on its active metabolite, 
aprepitant. Some early studies of fosaprepitant in the clinical 
setting are available, however they tend to involve small 
numbers of patients and do not reflect best practice dose 
regimens as recommended by current guidelines. Therefore, 
much of the evidence presented here relates to aprepitant, 
although outcomes can be considered equally relevant to the 
efficacy of fosaprepitant.
The literature search conducted for this analysis retrieved 
evidence available subsequent to the publication of a previous 
review by Chrisp.1 Five further studies on aprepitant were 
identified that investigated the efficacy of aprepitant for 
CINV in both first line11,19,20 and salvage therapy,21 along with 
a study of the tolerability of fosaprepitant and bioequivalency 
to aprepitant.14 An early clinical study investigating the use 
of fosaprepitant22 was also identified.
A variety of endpoints are used in the determination of the 
efficacy of drugs for treatment of CINV . The main indicator of 
success in studies of these medications tends to be “complete 
control,” which is usually defined as no nausea and no use 
of rescue medication and forms the basis of much of the 
analysis of evidence in this review. Other endpoints included 
measurements of nausea [either percentage of patients expe-
riencing no significant nausea or a subjective assessment by 
the patient of their own symptoms using a visual analog scale 
(VAS) from 0 to 100, with 100 = worst nausea possible] and 
the percentage of patients free from emesis.
Bioequivalence of fosaprepitant 
to aprepitant
In a randomized, open label, crossover study by Lasseter and 
colleagues,14 an intravenous dose of fosaprepitant 115 mg 
was shown to have bioequivalence to oral aprepitant 125 mg 
(Table 3). Following pharmacokinetic analysis, similar abso-
lute values with the two drugs were observed for area under 
the concentration time curve (AUC), concentration after 
24 hours, and half-life. The time to maximum concentra-
tion was reached much sooner with fosaprepitant as would 
be expected for an intravenous formulation. Mean plasma 
aprepitant concentrations also differed for the first 4 hours 
postdose, with higher concentrations observed following 
intravenous fosaprepitant compared with oral aprepitant. 
Table 3 Level 2 evidence of the bioequivalence of fosaprepitant 
to aprepitant
Variable Geometric meana
   Aprepitant 
125 mg
Fosaprepitant 
115 mg
AUC0–∞ (ng.h/mL) 27 759 29 611
AUC0–∞ ratio 1.13
(fosaprepitant/aprepitant) 90%Cib: 1.06, 1.20
Cmax (ng/mL) 1354 3095
Cmax ratio 2.47
(fosaprepitant/aprepitant) 95% Ci: 2.25, 2.71
C24 h (ng/mL) 494 504
tmax(h)a 4.0 0.25
t1/2(h)a 14.0 13.6
Copyright © 2007.   Adapted with permission from Lasseter KC, Gambale J, Jin B, 
et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.   
J Clin Pharmacol. 2007;47:834–840.
Notes: aMedian for tmax and harmonic mean for t1/2. b95% Ci not reported.
Abbreviations: AUC, area under the concentration-time curve; C, concentration; 
CI, confidence interval; t, time.Core Evidence 2010:5 82
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Following this initial period, concentrations remained almost 
identical in the two dose groups.
Bioequivalence was ultimately determined by calculating 
the confidence interval for the AUC geometric mean ratio of 
fosaprepitant to aprepitant (Table 3). Both the 90% and 95% 
confidence interval limits fell within predefined bounds of 
0.8, 1.25 and therefore supported the proposed bioequiva-
lence hypothesis.
These findings indicate that the evidence pertaining to 
aprepitant can be applied directly in evaluating the use of 
fosaprepitant for managing CINV .
Control of CiNv with highly emetogenic 
chemotherapy
Two studies of the use of fosaprepitant in the treatment 
of CINV following cisplatin-based chemotherapy have 
been conducted.22,23 In the study by Cocquyt and col-
leagues,22 53 patients receiving cisplatin-based chemotherapy 
(50–100 mg/m2) were given fosaprepitant 60 or 100 mg (later 
standardized to 100 mg for all patients following lack of symp-
tom control at the lower dose) or ondansetron 32 mg on day 1 
only and in the absence of any other concomitant medications. 
Patients receiving fosaprepitant exhibited complete control 
(no emesis or use of rescue medication) in the acute phase in 
37% of cases, with 48% of patients experiencing complete 
symptom control in the delayed phase. This compared to 
48% and 17% of patients, respectively, in the ondansetron 
group. Similar results were also observed by Van Belle and 
colleagues.23 In a study of 179 patients receiving chemotherapy 
with cisplatin 70 mg/m2, patients receiving fosaprepitant 
and dexamethasone on day 1 experienced complete control 
of symptoms in 36% of cases in the acute phase, with 46% 
of patients exhibiting complete control in the delayed phase. 
In patients who were followed up with aprepitant treatment 
on days 2–5 following fosaprepitant on day 1, outcomes were 
slightly better, with complete control observed in 44 and 59% 
of patients in the acute and delayed phases, respectively. In a 
third treatment group, who received ondansetron and dexa-
methasone on day 1, fewer patients (38%) experienced reduced 
delayed phase symptom control, however, a greater proportion 
of patients (83%) exhibited complete control in the acute phase 
when compared with both of the fosaprepitant groups.
Although both of these early studies are relatively small 
and were performed before dosages and combinations had 
been standardized, they demonstrate marked improvement 
in the management of CINV symptoms in the delayed phase 
following treatment with fosaprepitant. However, as the 
antiemetic drug regimens employed in these trials did not 
follow current best practice as set out in clinical guidelines, 
the observed efficacy in general, especially in the acute phase, 
was relatively low.
As previously described, fosaprepitant activity is directly 
attributable to its active form aprepitant, with strong evidence 
supporting the use of aprepitant alongside other antiemetics 
in preventing nausea and emesis following highly emeto-
genic chemotherapy with cisplatin 70 mg/m2.1 Aprepitant 
administered on day 1 in conjunction with ondansetron 
and dexamethasone, and followed up with aprepitant and 
dexamethasone on days 2 and 3, with a final dose of dexa-
methasone on day 4, can prevent both emesis and the need 
for further rescue medication in up to ∼90% of patients in the 
acute phase and up to 75% in the delayed phase of CINV .
An additional recent trial19 identified by the literature 
search performed for this review provides further evidence 
for the efficacy of aprepitant in the treatment of CINV 
following highly emetogenic chemotherapy. There were 
no statistically significant differences in complete response 
observed in both the acute and delayed phases of CINV 
when aprepitant was given on day 1 in a single-dose regimen 
with palonosetron and dexamethasone (66.7% and 63.0%, 
respectively), compared with a 3-day aprepitant regimen 
(70.4% complete response in the acute phase, 59.3% in the 
delayed phase). Outcomes with both of these regimens were 
considerably better than in the control group of patients 
receiving palonosetron and dexamethasone (Table 4).
However, it should be noted that the complete response 
rate in this trial was ∼15%–20% lower than in earlier trials 
that used an alternative serotonin antagonist, ondansetron, in 
combination with the same dose regimen of aprepitant and 
dexamethasone.9,10 Further studies may be needed to investigate 
the efficacy of palonosetron in combination with aprepitant for 
antiemetic treatment in highly emetogenic chemotherapy.
Other outcomes related to incidence of acute and delayed 
vomiting with aprepitant were favorable, with similarly high 
emesis prevention rates observed with both the 3-day (92.9%) 
and 1-day (92.6%) aprepitant regimens. Low nausea scores 
were also reported in both treatment arms (Table 4).
Current evidence therefore remains in support of the use of 
aprepitant for prevention of acute and delayed CINV in highly 
emetogenic chemotherapy, and also indicates an equivalent 
response with 3 day versus 1 day administration of aprepitant.
Control of CiNv with moderately 
emetogenic chemotherapy
The earlier review by Chrisp1 also noted the efficacy 
of aprepitant for prevention of CINV in moderately Core Evidence 2010:5 83
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Table 4 Outcomes achieved with aprepitant in the prevention of CiNv due to highly or moderately emetogenic chemotherapy
Emetogenicity  Level of 
evidence
Design  CT 
regimen
Antiemetic 
treatment
Outcome  Reference 
Acute phase Delayed phase
Complete 
response 
(%)a
Emesis  
free  
(%)
Nausea 
 
Complete 
response 
(%)a
Emesis 
free 
Nausea 
 
  
 
High 2 Si, 
rPCT, 
DB
Cis based  
 50 mg/m2 
or  
Ant and Cyc 
combination,  
1 cycle
Day 1:  
Ap125 mg + 
Dex 12 mg + 
Pal 0.25 mg 
Day 2–3:  
Ap 80 mg + 
Dex 8 mg  
Day 4: Dex  
8 mg (n = 29)
66.7 96.4 0b 63.0 92.9 Day 2  4b 
Day 3  1.5b 
Day 4  3.5b 
Day 5  0b
Herrington 
et al.19
Day 1:  
Ap125 mg + 
Dex 12 mg 
+ Pal  
0.25 mg  
Day 2–3:  
Pla + Dex 
8 mg  
Day 4: Dex  
8 mg (n = 30)
70.4 100 0b 59.3 92.6 Day 2  1b 
Day 3  2.5b 
Day 4  2.5b 
Day 5  0b
Day 1: Pla + 
Dex  
18 mg + Pal  
0.25 mg Day 
2–3: Pla + 
Dex 8 mg 
Day 4: Dex  
8 mg (n =16)
56.2 93.8 0b 31.2 50 Day 2  0b 
Day 3  2.5b 
Day 4  2.5b 
Day 5  0b
Moderate 3 MC, SA, 
OL
Car, Epi, ida, ifo, 
iri, Mit, or Oxa; 
Met 250 
mg/m2; Cyc  
1500 mg/m2; 
Dox   
25 mg/m2; 
or Cis  
50 mg/m2
Day 1:   Ap  
125 mg +  
Dex 12 mg + 
Pal 0.25 mg 
Day 2–3:  
Ap 80 mg + 
Dex 8 mg  
(n = 58)
88 93 71c 78 93 53c Grote 
et al.11
Moderate 2 Si, 
rPCT, 
DB
Dox 
60 mg/m2 +  
Cyc  
600 mg/m2
Day 1:   Ap 
125 mg + 
Dex 12 mg 
+ Ond 8 mg 
bid Day 2–3:  
Ap 80 mg qd
72.1 72.1 62.3c 64.4 75.6 47.3c Yeo et al.20
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
Day 1: Dex  
20 mg +  
8 mg Ond  
bid Day 2–3: 
Ond 8 mg bid
72.6 
 
 
 
74.2 
 
 
 
59.7c 
 
 
 
57.8 
 
 
 
67.4 
 
 
 
59.5c 
 
 
 
 
 
 
 
Notes: aDefined as no vomiting or use of rescue medication. bMedian vAS score (0 = none; 100 = worst). cPercentage of patients free from nausea.
Abbreviations:   Ant, anthracycline;   Ap, aprepitant; bid, twice daily; Car, carboplatin; CiNv, chemotherapy-induced nausea and vomiting; Cis, cisplatin; CT, chemotherapy; Cyc, 
cyclophosphamide; DB, double-blind; Dex, dexamethasone; Dox, doxorubicin; Epi, epirubicin; ida, idarubicin; ifo, ifosfamide; iri, irinotecan; MC, multicenter; Met, methotrexate; 
Mit, mitoxantrone; OL, open label; Ond, ondansetron; Oxa, oxaliplatin; Pal, palonosetron; Pla, placebo; qd, once daily; rPCT, randomized placebo-controlled trial; SA, single arm; 
Si, single institution;   vAS, visual analog scale.Core Evidence 2010:5 84
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emetogenic chemotherapy. A major study showed that a 3-day 
regimen of aprepitant, together with the serotonin antagonist 
ondansetron plus dexamethasone on day 1, was able to com-
pletely control CINV in 76% of patients in the acute phase 
and 55% in the delayed phase, and more successfully than a 
regimen of ondansetron and dexamethasone alone.24
A more recent study by Grote and colleagues11 further 
supports the use of aprepitant for treatment of nausea and 
vomiting associated with moderately emetogenic drugs 
used in chemo  therapy. This is the first trial to investigate 
aprepitant in combination with palonosetron and dexa-
methasone for treatment of both acute and delayed CINV 
following moderately emetogenic chemotherapy. The 
complete response rate was 88% in the acute phase and 
78% in the delayed phase. These results indicate that this 
regimen provides effective relief of symptoms (Table 4) 
and is more effective than a combination of aprepitant and 
dexamethasone, plus an alternative serotonin antagonist.
Interestingly, the use of palonosetron plus aprepitant 
appears to be much more effective in the management of 
CINV in moderately emetogenic chemotherapy compared with 
the less impressive results described above for highly emeto-
genic chemotherapy, and is cited by the authors as a potential 
reason for the considerable improvement in complete response 
rates. Further reasons for the high efficacy rates observed 
may also be attributable to the inclusion of patients who had 
experienced only mild nausea with previous chemotherapy 
sessions, and a lower proportion of patients receiving the more 
emetogenic anthracyline/cyclophosphamide combination.
A study has also been conducted to investigate the only 
moderately emetogenic chemotherapy regimen for which 
aprepitant-based therapy of CINV has specifically been 
approved by guidelines. Yeo and colleagues20 performed a trial 
in Chinese patients with breast cancer receiving the chemo-
therapeutic regimen of doxorubicin and cyclophosphamide. 
Results indicate that aprepitant has a similar efficacy to 
standard treatment in the acute phase (72.1% versus 72.6% 
complete control) but provides greater complete control 
(64.4% versus 57.8%) and more effective prevention of 
emesis (75.6% versus 67.4%) in the delayed phase than the 
standard treatment (Table 4).
These data provide further evidence of the efficacy 
of aprepitant for CINV prevention following moderately 
emetogenic chemotherapy.
Salvage therapy
Aprepitant has also been used as rescue medication in 
patients for whom standard antiemetic drug combinations 
have failed to control CINV . A study performed by Oechsle 
and colleagues21 investigated the efficacy of aprepitant as sal-
vage therapy in patients refractory to previous treatment with 
serotonin antagonists and dexamethasone following a variety 
of chemotherapy, including cisplatin- (35%) and anthracycline-
based (30%) regimens. Addition of aprepitant to the antiemesis 
treatment schedule led to a decrease in the number of patients 
suffering from nausea for 4 days from 24 (71%) to four (12%) 
(P  0.001), and an increase in the number of patients with no 
emesis from three (9%) to 26 (76%) (P 0.001) (Table 5).
Tolerability
Aprepitant has been shown to have a safety profile similar to 
that of nonaprepitant-based antiemetic regimens.1 Adverse 
events are mild and infrequent.
As fosaprepitant is rapidly converted to aprepitant 
following administration, it would be expected to have 
similar tolerability to its active metabolite and studies 
involving fosaprepitant have shown this to be the case. In the 
trial conducted by Cocquyt and colleagues22 fosaprepitant 
had an equivalent safety profile to the comparator drug 
ondansetron when used to treat CINV in highly emetogenic 
chemotherapy, except for an increased incidence of diar-
rhea (60% with fosaprepitant versus 9% with ondansetron). 
No serious adverse events were considered to be study drug 
related. Another trial investigating fosaprepitant antiemesis 
in highly emetogenic chemotherapy also found no signifi-
cant difference in adverse events versus standard regimens, 
although an increase in the incidence of diarrhea was again 
Table 5 response to aprepitant salvage therapy; comparison of 
first chemotherapy cycle with added aprepitant and preceding 
cycle without aprepitant
Response Patients, n
  Prior to aprepitant With aprepitant
Nausea, days
0–1 0 18
2–3 10 12
4–5 16 3
5 8 1
vomiting,a days
0 3 26
1 5 8
2–3 18 0
3 8 0
Copyright © 2006. Adapted with permission from Oechsle K, Müller Mr, Hartmann 
JT, Kanz L, Bokemeyer C.   Aprepitant as salvage therapy in patients with chemotherapy-
induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and 
dexamethasone. Onkologie. 2006;29:557–561.
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observed (23% in both fosaprepitant arms versus 5% in the 
ondansetron/dexamethasone control group).23
These findings were largely in agreement with those 
from a specific tolerability study.14 Fosaprepitant was well 
tolerated in doses of 90–150 mg; all adverse events were 
mild or moderate, with headache (3% in the 115 mg group) 
and infusion-site pain (10.4% in the 100 mg group and 7.6% 
in the 115 mg dose group) most commonly reported. Vital 
signs, physical examination, and electrocardiograms showed 
no sign of being affected by treatment.
Concerns over interactions with other drugs have been 
investigated, as aprepitant is metabolized by cytochrome 
P450 (CYP) 3A4 and coadministration with other drugs also 
metabolized by this enzyme may have clinical significance. 
The evidence for this is conflicting. One study observed 
an increase in serious adverse events in patients receiving 
aprepitant concomitantly with the CYP3A4-metabolized 
etoposide, vinca alkaloids, and taxanes, compared with 
those on standard antiemetics.10 However, another showed 
no significant difference in adverse events in patients 
receiving aprepitant compared with other antiemetics, while 
receiving chemotherapy with drugs metabolized by CYP3A4 
(etoposide, vinorelbine, and paclitaxel).9
It is advisable to avoid potential interactions in the absence 
of conclusive evidence and further guidance is provided in 
the Dosage, administration, and formulation section.
Economic evidence
Two recent studies have compared the cost-effectiveness 
ratio of an antiemetic regimen of aprepitant in combination 
with a serotonin antagonist and a corticosteroid, with a con-
ventional regimen consisting of a serotonin antagonist and 
a corticosteroid for CINV treatment in highly emetogenic 
chemotherapy.25,26 Each of the regimens was assessed in 
models based on published data from major phase III trials 
in patients receiving chemotherapy with cisplatin.9,28
Moore and colleagues26 created a Markov model with 
a 28-day cycle length in which 5 cycles of chemotherapy 
were modeled (Table 6). Within the model, patients could 
experience one of four health states: 1) neither acute nor 
delayed CINV; 2) acute CINV only; 3) delayed CINV only; 
or 4) both acute and delayed CINV . Each category of outcome 
was assigned a “healthy day equivalent” (HDE) value (the 
number of days of optimal health considered equivalent to the 
time spent in the various health states as assessed by patients 
themselves). Published clinical trial data9 were used to estab-
lish probabilities for these outcomes, and costs (reported in 
2005 US dollars) were calculated from the payer perspective. 
Data were analyzed to estimate the number of HDEs during 
the 5 cycles of chemotherapy, which was converted to 
quality-adjusted life-years (QALY) for cost-utility analysis. 
The incremental cost-effectiveness ratio (ICER), namely 
the cost per QALY gained with aprepitant in combination 
with ondansetron plus dexamethasone, over a regimen of 
ondansetron and dexamethasone only was then calculated 
and was estimated to be $US97,429 over a period of five 
chemotherapy cycles.
Lordick and colleagues25 conducted a similar, extensive 
analysis looking at the cost effectiveness of aprepitant based 
on a pooled analysis27 of two trials in patients receiving 
antiemetic prophylaxis for highly emetogenic chemo-
therapy. A model of health states was constructed based on 
clinical endpoints in the clinical trials: complete protection 
(no emesis, no rescue therapy, maximum nausea 25 mm 
on a 100 mm VAS); complete response at best (no emesis, 
no rescue therapy, maximum nausea 25 mm on a 100 mm 
VAS); and incomplete response (complement of the preced-
ing states: some emesis or rescue therapy). These states were 
then assigned utilities (ie, preferences the individual has for 
a particular health outcome) on a scale of 0 to 1. Complete 
protection was graded as 0.9, complete response at best as 
0.7, and incomplete response as 0.2. In conjunction with the 
recorded number of days spent in each health state for each 
patient, the utility values were used to calculate number of 
quality-adjusted life-days at the end of 5 days of chemo-
therapy, which was then extrapolated to arrive at a clinical-
effectiveness measure in terms of QALY (Table 6).
In this analysis, the ICER was estimated at €28,891 
(undiscounted year 2004 euros) over a period of one 5-day 
chemotherapy cycle.
Although a cost per QALY threshold has not yet been set 
in Germany where this study originated, aprepitant appears 
to represent acceptable value in the context of thresholds 
in other countries such as the £30,000 put forward by the 
National Institute for Health and Clinical Excellence.28
In terms of cost-effectiveness thresholds, the ICER 
arrived at by Moore and colleagues26 of  $US97,429 is almost 
twice as much as the commonly applied figure of $US50,000 
used to assess the cost effectiveness of new therapies in 
the US.29,30 However, this was defined in the 1970s and is 
based on end-stage renal disease treatment, the cost of which 
is now believed to be more than $US120,000.31 Therefore, the 
cost of aprepitant treatment may be considered reasonable 
using this higher threshold.
A third economic analysis32 has recently found that an 
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Table 6 Economic evidence from three cost effectiveness analyses of aprepitant versus standard therapy in treatment of CiNv
Treatment 
 
 
Duration of 
assessment  
period 
Chemotherapy  
regimen 
 
Drug 
costs per 
regimen 
per cycle
Total  
costs 
 
Days of  
health  
gained 
QALYs  
gained 
 
CER 
 
 
ICER of  
aprepitant  
regimen 
Reference 
 
 
Ap regimen 
Day 1:  
Ond 32 mg + Dex  
12 mg + Ap 125 mg
One 5-day cycle of 
chemotherapy
HEC  
(Cis 70 mg/m2)
€225.05 €380.04a 3.53a 0.0097a Nr €28 891a Lordick 
et al25 
(Based on 
de wit 
et al27)
Day 2–3:  
Ap 80 mg + Dex 8 mg
Day 4: 
Dex 8 mg (n = 514)
Control regimen €151.67 €330.44a 2.90a 0.0080a Nr
Day 1:  
Ond 32 mg + Dex 20 mg
Day 2–4:  
Dex 8 mg bid  
(n = 518)
Ap regimen
Day 1: 
Ond 32 mg +  
Dex 12 mg + Ap 125 mg
Five cycles of 
chemotherapy
HEC  
(Cis 70 mg/m2)
$US318.02 $US1393b 1 4.40b 0.040b $US34 825b $US97 429b Moore 
et al26 
(Based on 
Hesketh 
et al9)
Day 2–3: 
Ap 80 mg + Dex 8 mg
Day 4: 
Dex 8 mg
Control regimen
       
 
$US136.19
 
 
$US711b
 
 
11.93b
 
 
0.033b
 
 
$US21 545b
Day 1: 
Ond 32 mg + Dex 
20 mg
Day 2–4: 
Dex 8 mg bid  
(hypothetical cohort 
of patients) 
Ap regimen:
Day 1:  
Ap 125 mg + Ond  
32 mg + Dex12 mg 
Day 2–3:  
Ap 80 mg + Dex 8 mg 
Day 4: Dex 8 mg  
(n = 484 in total)
Multiple cycles HEC  
(Cis 70 mg/m2)
Nr Trial 
based: 
€605c  
real life 
based: 
€554c
Nr 0.142c Nr Ap 
dominant
Annemans 
et al32 
(Based on 
Schmoll 
et al;34 de 
wit et al;27 
Herrstedt 
et al33)
Control regimen
Day 1: 
Ond 32 mg + Dex  
20 mg Day 2–4: Ond  
8 mg bid + Dex  
8 mg bid
Nr Trial 
based:  
€671c  
real life 
based: 
€629c
Nr 0.139c Nr
Ap regimen
Day 1: 
Ap 125 mg + Ond 
8 mg + Dex 12 mg 
before chemotherapy 
and Ond 8 mg  
after 8 h
MEC (Cyc 
750–1500 mg/m2 
alone or Cyc  
500–1500 mg/m2 +   
Dox  60 mg/m2   
or Epi  
 100 mg/m2)
Nr Trial 
based: 
€348c 
real life 
based:  
€392c
Nr 0.133c Nr
(Continued)Core Evidence 2010:5 87
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emetogenic chemotherapy is not only more effective, but 
also less expensive than standard therapy.
This study utilized two scenarios for highly and 
moderately emetogenic chemotherapies: one scenario was 
based on two clinical studies,33,34 the second on a real world 
clinical setting in Belgium. In this analysis only two health 
states were considered: complete response at best, and 
incomplete response, which were weighted as 0.7 and 0.2, 
respectively, in line with the protocol used by Lordick and 
colleagues.25 Costs were considered from a payer perspec-
tive and were reported in year 2005 Euros. The overall costs 
included both the expenditure on preventative study drugs 
and also the cost of CINV-related treatment such as rescue 
medication and hospitalization. In the “real life” situation, 
differences between medications administered during the 
trial and doses actually administered during normal clinical 
practice were taken into account.
Results are presented in Table 6 and demonstrate the cost 
effectiveness of aprepitant regimens. Compared with standard 
antiemetic therapy, aprepitant was associated with a gain of 
0.003 QALYs and per patient savings of  €66.84 (trial scenario) 
and €74.62 (“real life” scenario) in highly emetogenic chemo-
therapy. The corresponding values in moderately emetogenic 
chemotherapy were €0.014, €17.95, and €21.70.
It should be noted that all the economic analyses 
conducted so far have been on studies with aprepitant. 
Although bioequivalent, the intravenous formulation of 
fosaprepitant will affect its cost effectiveness. For example, 
it must be reconstituted in solution from a powder, requires 
equipment and skilled personnel for its administration, and 
has the potential for adverse effects such as infusion-site 
reactions, all of which have the potential to increase costs. 
Further studies would therefore be welcome to investigate 
the cost effectiveness of fosaprepitant-based regimens.
Resource utilization
CINV is a considerable burden on the resources of health 
care providers. In a European study, across 208 cycles of 
moderately to highly emetogenic chemotherapy, the total 
cost of CINV prophylaxis and treatment was €53.62.35 
In the US, costs are even higher; an office-based oncologist 
treating an episode of CINV incurred estimated labor costs 
of $US175.36 However, costs can be reduced through the 
prophylaxis of CINV . A study analyzing resources utilized 
in the hypothetical treatment of 1000 patients with aprepi-
tant plus standard antiemetics found that savings in overall 
medical resource costs would offset any increase in costs due 
to the addition of aprepitant by 58.7%.37
A more indepth economic analysis has now confirmed 
these findings. Lordick and colleagues25 deduced that the total 
treatment cost (expenditure on antiemetic drugs plus other 
health care resources) of aprepitant in a 4-day combination 
regimen with ondansetron and dexamethasone was €380.04 
per patient; an increase of  €49.60 over standard treatment with 
ondansetron and dexamethsone only. Aprepitant accounted 
for €85.92 of the total treatment cost, and thus the cost offset 
due to aprepitant was €36.32 (42%). Cost offsets were largely 
as a result of reduced health care resource utilization with the 
aprepitant regimen (€154.99 per patient versus €178.77 with 
standard therapy), where savings mainly arose from lower 
doses of dexamethasone (€12.54), decreased use of rescue 
medication (€7.38), and less hospitalization (€15.86).
Further savings could be made through changes in the dose 
frequency of aprepitant. Evidence for the equivalent efficacy 
Table 6 (Continued)
Treatment 
 
 
Duration of 
assessment  
period 
Chemotherapy  
regimen 
 
Drug 
costs per 
regimen 
per cycle
Total  
costs 
 
Days of  
health  
gained 
QALYs  
gained 
 
CER 
 
 
ICER of  
aprepitant  
regimen 
Reference 
 
 
Control regimen
Day 1: 
Ond 8 mg + Dex 
20 mg + Pla before 
chemotherapy and 
Ond 8 mg after 8 h
Nr Trial 
based:  
€366c 
real life 
based: 
€414c
Nr 0.119c Nr
Day 2–3: Ond  
8 mg bid (n = 428)
                          
Notes: aPer 5-day cycle of chemotherapy. bPer 5 cycles of chemotherapy. cPer patient.
Abbreviations: Ap, aprepitant; bid, twice daily; CEr, cost-effectiveness ratio; CiNv, chemotherapy-induced nausea and vomiting; Cis, cisplatin; Cyc, cyclophosphamide; Dex, 
dexamethsone; Epi, epirubicin; HEC; highly emetogenic chemotherapy; iCEr, incremental cost-effectiveness ratio; MEC; moderately emetogenic chemotherapy; Nr, not reported; 
Ond, ondansetron; Pla, placebo; QALY, quality-adjusted life-year.Core Evidence 2010:5 88
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of 1-day versus 3-day aprepitant in highly emetogenic 
chemotherapy has been demonstrated,19 with associated 
potential reduction in medication costs. This, however, needs 
further confirmation.
Patient group/population
Fosaprepitant is approved for use in the prevention of acute 
and delayed nausea and vomiting associated with initial and 
repeated courses of highly and moderately emetogenic cancer 
chemotherapy, including high-dose cisplatin, in combination 
with other antiemetic agents.38 Recent updates to the MASCC 
and NCCN guidelines now incorporate fosaprepitant as a 
recommended alternative to aprepitant in frontline therapy 
for acute phase CINV in patients receiving highly emetogenic 
chemotherapy, and also for those patients receiving an anthra-
cycline plus cyclophosphamide. The NCCN also supports 
the use of fosaprepitant in a further select group of patients 
receiving cisplatin, carboplatin, doxorubicin, epirubicin, 
ifosfamide, irinotecan, and methotrexate, for acute CINV 
only and as an alternative to aprepitant (Table 2).
Dosage, administration, 
and formulations
Fosaprepitant (115 mg) may be substituted for aprepitant 
(125 mg) on day 1 only of the antiemetic drug regimen and 
should be given prior to chemotherapy as a 15-min infusion. 
The drug is available as a soluble powder that should be 
reconstituted in solutions of proven compatibility, and is 
incompatible with solutions containing divalent cations 
(eg, Ca2+, Mg2+) including lactated Ringer’s solution 
and Hartmann’s solution.38 Fosaprepitant should not be 
administered as a bolus, nor should it be administered intra-
muscularly or subcutaneously. No dosage adjustment is 
necessary for the elderly, patients with renal insufficiency or 
end-stage renal disease undergoing hemodialysis, or patients 
with mild-to-moderate hepatic insufficiency.
The action of aprepitant as a CYP3A4 inhibitor and 
inducer means it should not be concomitantly adminis-
tered with pimozide, terfenadine, astemizole, or cisapride. 
Aprepitant should also be used with caution in patients 
receiving any other medications that are either metabolized 
through, act as substrates for, or inhibit or induce CYP3A4. 
These include ergot alkaloid derivatives and St John’s wort. 
Coadministration of aprepitant and irinotecan should also 
be approached with caution as increased toxicity may result 
from this combination.
Patients on chronic warfarin therapy should have their 
international normalized ratio of prothrombin time closely 
monitored for 2 weeks after a 3-day fosaprepitant/aprepitant 
regimen, and patients using hormonal contraception should 
switch to an alternative method during and for two months after 
the last dose of treatment with fosaprepitant or aprepitant.
The dose of corticosteroid administered with fosaprepi-
tant for antiemesis should be adjusted in the same way as 
aprepitant regimens. This includes a reduction of 50% in the 
dose of dexamethasone and oral methylprednisolone, and a 
25% reduction of intravenous methylprednisolone.
Place in therapy
The NK1 receptor antagonist aprepitant is now established 
as a frontline treatment in combination with other antiemetic 
medications for CINV in highly and some types of moder-
ately emetogenic chemotherapy. Guidelines issued by the 
American Society of Clinical Oncology (ASCO), European 
Society for Medical Oncology (ESMO), MASCC, and 
NCCN (Table 2) now recommend it for the management of 
CINV in all types of highly emetogenic chemotherapy, and 
a subset of moderately emetogenic chemotherapies using an 
anthracycline plus cyclophosphamide.
Fosaprepitant is a recently approved intravenous prodrug 
of aprepitant that has been shown to be bioequivalent. 
As an intravenous formulation, fosaprepitant offers poten-
tial benefits for patients who may be unable to tolerate oral 
medication during periods of nausea and emesis. Based on the 
clear evidence of aprepitant’s efficacy, fosaprepitant has now 
been included in guidelines for administration interchange-
ably with aprepitant on the first day of treatment with highly 
and some forms of moderately emetogenic chemotherapy 
for management of acute CINV . Studies with fosaprepitant 
have also demonstrated success in the treatment of delayed 
symptoms of CINV that may be an avenue for further 
investigation, as guidelines do not currently recommend it 
for this indication.
Economic evidence suggests that the increased costs 
of aprepitant-based treatment regimens can be partially 
offset by savings made in other health care resources, with 
some findings stating that absolute costs with an aprepitant 
regimen are in fact less than with standard therapy. Some data 
indicate that further savings could also be made by giving 
aprepitant on the first day only of a course of CINV treat-
ment as opposed to currently recommended administration 
over the first 3 days. However, it should be noted that, as an 
intravenous formulation, additional costs may be associated 
with the use of fosaprepitant.
A large body of evidence for the clinical efficacy of apre-
pitant is now well established, and results from new studies Core Evidence 2010:5 89
Fosaprepitant and aprepitant Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
continue to support its place in the treatment of CINV . The 
bioequivalence of fosaprepitant to aprepitant along with 
initial clinical trials indicate the potential of fosaprepitant as a 
further key component in the management of CINV . Further 
studies will help to supplement current evidence, particularly 
by firmly establishing successful treatment outcomes follow-
ing incorporation of fosaprepitant into the recently updated 
guidelines for acute CINV , and by continuing to investigate 
its clinical potential in the delayed phase.
In summary, fosaprepitant is a useful addition to the range 
of treatment options now available for CINV therapy associ-
ated with moderately or highly emetogenic chemotherapy. 
It has all the key benefits of aprepitant whilst providing a 
more convenient route of administration for patients who 
may struggle to tolerate oral medication.
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